ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Zydus Lifesciences announced that a recent USFDA inspection of its pharmacovigilance and post-marketing surveillance system at the company’s USA office concluded with nil observations.
CRISIL reaffirmed Zydus Lifesciences ratings: CRISIL AAA/Stable (LT) and A1+ (ST) on a Rs.4,724 Cr bank facility, plus CPs and NCDs. The stable outlook signals unchanged strong credit standing.
Zydus Lifesciences' subsidiary, ZPUI, settled an antitrust litigation case for a total payment of USD 5.9 million, without admission of wrongdoing.
Zydus delivered robust FY27 Q1 results driven by strong India-branded formulations and U.S. generic resilience.
Zydus Lifesciences reported strong Q1 FY27 revenue growth of 22% YoY, driven by robust performance in India and International formulations, despite a decline in PAT and EBITDA margins.
Zydus Lifesciences Ltd reported revenue from operations of ₹8,017 Cr (+22.0% YoY) and net profit of ₹939.8 Cr (-35.9% YoY) for Q1 FY27.
Zydus delivered strong Q4 FY26 results with 16% YoY revenue growth and record 33.7% EBITDA margins, driven by US specialty and India branded formulations.
Zydus delivered a record-breaking FY26 with 17% revenue growth and peak EBITDA margins of 31.2%, significantly exceeding internal expectations.
Zydus Lifesciences reported strong FY26 performance with 16% YoY revenue growth and EBITDA margins expanding to 31.2%. Strategic focus remains on US specialty/rare diseases and domestic chronic therapy leadership.
Zydus Lifesciences Ltd reported revenue from operations of ₹7,587 Cr (+16.2% YoY) and net profit of ₹1,272 Cr (+8.7% YoY) for Q4 FY26.